Latest stories on GPCR
Structure Therapeutics (GPCR) Highlights Two Aleniglipron Posters at ObesityWeek 2026, Focusing on ACCESS Trial Data
October 20, 2026
MarketChameleon58 · neutralproduct/pr
Structure Therapeutics (GPCR) Sets Two ObesityWeek 2026 Posters Around Aleniglipron’s ACCESS Trials
October 20, 2026
MarketChameleon56 · neutralproduct/pr
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
GlobeNewswire53 · neutralproduct/pr
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
StockTitan56 · neutralproduct/pr
Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralproduct/pr
Structure Therapeutics: The Amylin Data Changes The Math
Seeking Alpha67 · bullishproduct/pr
Citizens reiterates Structure Therapeutics stock rating on trial data
Investing.com Analyst Ratings56 · neutralanalyst
Structure Therapeutics falls after trial data for lead obesity drugs
Seeking Alpha34 · bearishearnings
Jefferies raises Structure Therapeutics stock target on amylin data
Investing.com Analyst Ratings61 · neutralanalyst
Structure Therapeutics reports ACCG-2671, aleniglipron trial results
The Fly59 · neutralproduct/pr
Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results
TipRanks67 · bullishproduct/pr
Structure Therapeutics Inc. (GPCR) files 8-K
SEC 8-K50 · neutralgeneral
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
GlobeNewswire67 · bullishproduct/pr
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
Business Insider67 · bullishproduct/pr
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Business Insider56 · neutralgeneral
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
GlobeNewswire56 · neutralgeneral
Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030
Seeking Alpha73 · bullishproduct/pr
Citizens lowers Structure Therapeutics stock price target on GLP agonist
Investing.com Analyst Ratings34 · bearishanalyst
Structure Therapeutics Price Target Raised To 111 From 101 At Canaccord
The Fly61 · neutralanalyst
Structure Therapeutics Price Target Lowered To 97 From 100 At Citi
The Fly42 · neutralanalyst
Structure Therapeutics price target lowered to $110 from $113 at Citizens
The Fly42 · neutralanalyst
Structure Therapeutics Inc. (GPCR) files 8-K
SEC 8-K50 · neutralgeneral
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
StockTitan63 · neutralearnings